Search
Cefradine
go.drugbank.com/drugs/DB01333ApprovedWithdrawnA semi-synthetic cephalosporin antibiotic.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersSynonyms: (6R,7R)-7-((R)-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, (6R,7R)-7-{[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acidObinutuzumab
go.drugbank.com/drugs/DB08935ApprovedInvestigational[L54521] First approved by the FDA on February 26, 2016,[L54531] obinutuzumab is used to treat chronic lymphocytic leukemia, follicular lymphoma, and lupus nephritis.[L54521] … Obinutuzumab is a humanized anti-CD20 monoclonal antibody designed to treat B-cell malignancies.
Categories: CD20 (Clusters of Differentiation 20) inhibitorsProducts: GAZYVA 1000 MG/ 40 ML CONCENTRATE FOR SOLUTION FOR INFUSION, GAZYVA ® CONCENTRADO PARA SOLUCIÓN PARA INFUSIÓN 1000 MG / VIAL 40 MLDrospirenone
go.drugbank.com/drugs/DB01395ApprovedInvestigational[L33199,L33174] Aside from its contraceptive effects, drospirenone is used with estrogens to control acne and premenstrual dysphoric disorder (PMDD). … Drospirenone has been the subject of widespread safety concern due to the possibility of an increased risk of venous thromboembolism associated with its use.
Mixtures: Lo-Zumandimine, VERONIQ ® 3 MG / 30 MCGCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAlfuzosin
go.drugbank.com/drugs/DB00346ApprovedThe prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. … Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: XATRAL XL 10 MG, ALFUTOR ER TABLETS 10 MGIbutilide
go.drugbank.com/drugs/DB00308ApprovedIt is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR).
Products: Fybrio 1 mg/10 ml I.V. Enjeksiyonluk Çözelti, 1 ADET, Corvert 87 Mikrogramm/ml InfusionslösungWarfarin
go.drugbank.com/drugs/DB00682ApprovedInvestigationalWarfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. … Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: PLASORİN 10 MG TABLET, 28 ADET, WARFMADİN 10 MG TABLET, 28 ADETFurazolidone
go.drugbank.com/drugs/DB00614InvestigationalVet approvedFurazolidone binds bacterial DNA which leads to the gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
Synonyms: 3-(5'-Nitrofurfuralamino)-2-oxazolidone, 3-[(5-Nitrofurylidene)amino]-2-oxazolidoneInternational brands: Dependal-MErgoloid mesylate
go.drugbank.com/drugs/DB01049Approved[A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued. … [T90] The derivatives of this fungus are identified to be about 350 different substances from which the components of the ergoloid mesylate mixture are composed of the dihydrogenated ergot alkaloid derivatives
Synonyms: co-dergocrine mesilate, co-dergocrine mesylateMixtures: TOTERJİN DAMLA, 50 CCEcallantide
go.drugbank.com/drugs/DB05311ApprovedEcallantide is a recombinant 60-amino-acid protein produced in _Pichia pastoris_ yeast cells that contains three intramolecular disulfide bonds [FDA Label]. … The amino acid sequence of two compounds differ by seven amino acids [L1458].
Products: KALBITOR® 10 MG / MLMacitentan
go.drugbank.com/drugs/DB08932ApprovedInvestigational[L35890] It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] in part due to its lower risk of hepatotoxicity. … [L39105] It was subsequently approved by the FDA in March 2024.[L50622]
Mixtures: OPSYNVI® (MACITENTAN/TADALAFILO) 10MG/40 MG TABLETAS RECUBIERTASCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates